TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Files An 8-K Other Events
Item 8.01
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Files An 8-K Other Events
On March 9, 2020, TRACON Pharmaceuticals, Inc. and Santen Pharmaceutical Co. issued a joint press release announcing the discontinuation of development of DE-122 for Wet AMD based on top-line data from the recently completed Phase2a AVANTE clinical study. Top-line data indicated DE-122 did not improve visual acuity when combined with Lucentis as compared to single-agent Lucentis.
The press release issued on March 9, 2020 is attached hereto as Exhibit 99.1.
Tracon Pharmaceuticals, Inc. Exhibit
EX-99.1 2 tcon-ex991_6.htm EX-99.1 tcon-ex991_6.htm Exhibit 99.1 Santen and TRACON Discontinue Development of DE-122 for Wet Age-Related Macular Degeneration March 9,…
To view the full exhibit click here
About TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company’s lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.
